Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 4/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26091409 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26092218 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26094516 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26091329 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26096332 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26095609 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26096250 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26092782 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26094015 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL26095598 | 0.98 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134471-A1 | METHOD FOR PRODUCING (METH)ACRYLOXY GROUP-CONTAINING ORGANOSILICON COMPOUNDS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4174076-A1 | METHOD FOR PRODUCING (METH)ACRYLOXY GROUP-CONTAINING ORGANOSILICON COMPOUNDS | Shin-Etsu Chemical Co., Ltd. (JP) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134471-A1 | METHOD FOR PRODUCING (METH)ACRYLOXY GROUP-CONTAINING ORGANOSILICON COMPOUNDS | HM13, RPS13, GRHPR | ATM 934/4885HCAR2 339/4885TSHR 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.